The topic of this article may not meet Wikipedia's general notability guideline .(January 2023) |
Riccardo Polosa (born in July 1961 in Catania) is an Italian respiratory physician. According to a paper published in BMC Public Health , he is the most prolific author in the field of electronic cigarettes, as of 2014. [1] "Full Professor of Internal Medicine and specialist of Respiratory Diseases and Clinical Immunology at the University of Catania as well as the Founder and Clinical Director of the Center for Tobacco Research and Scientific Director of the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) at the same University." [2] His research interests center on asthma, COPD, respiratory diseases, smoking-related diseases, smoking prevention and cessation, tobacco harm reduction, and new tobacco products. Since 2009, his research team has been involved in studies on the impact of e-cigarettes, and they were the first in the world to publish a randomized controlled trial on e-cigarettes.
The focus of his academic research has been historically centered upon the investigation of mechanisms of inflammation, biomarkers of disease activity, and novel drug target discovery in the area of respiratory medicine (asthma, COPD, rhinitis) and clinical immunology (allergic and autoimmune diseases). This has culminated with the participation of his research group in large EU funded pan-european research consortia (Unbiased BIOmarkers for the PREDiction of Respiratory Disease Outcome -U-BIOPRED; Airway Disease Predicting Outcomes through Patient Specific Computational Modelling – AIRPROM; Integral Rheumatology & Immunology Specialists Network – IRIS).
Polosa Riccardo received his bachelor's degree in medicine and surgery from University of Catania in 1986. He thereafter pursued specialisations in diseases of the respiratory system and tisiology[ check spelling ] in 1990 from the same university and clinical immunology and allergology in 1994 from University of Southampton. [3] He returned to university of Catania to pursue PhD in internal medicine. [3]
Riccardo Polosa pursued specializations in diseases of the respiratory system and physiology in 1990 from the University of Catania and clinical immunology and allergology in 1994 from the University of Southampton. In 1996 he pursued Ph.D. in Internal Medicine at the University of Florence with a thesis on "The role of adhesion molecules in the inflammatory response of allergic asthma" (Supervisor: Prof. L. Mughini). Since 2002 Polosa is a reviewer of the Italian Ministry of Health for ECM activities in the field of Respiratory Diseases and Clinical Immunology and Allergology.
His scientific interests concern: the pathogenetic mechanisms and treatment of asthma, COPD, and rhinitis. Environmental health problems include the incidence of allergic and respiratory diseases in urban areas and air pollution. Significant risk factors for new-onset asthma and progression of COPD.
In 2000, Polosa Riccardo was appointed Professor in University of Eastern Piedmont, while he continued to serve in various capacities at the department of Pneumology, Rheumatology, Immunological Diseases and Allergology and the center for Prevention and Treatment of Tobacco Smoking at University of Catania. [4] Polosa was appointed full professor of internal medicine at University of Catania in 2007 and was promoted as the director of the School of Specialization in Rheumatology in 2011. [5]
In 2018, Riccardo Polosa founded the Center of Excellence for the acceleration of Harm Reduction (CoEHAR), University of Catania, Italy. [4]
The CoEHAR aims at developing policy recommendations that would allow a more widespread diffusion of 'reduced-risk products', such as electronic cigarettes. [6] [7] [8] [9]
Riccardo Polosa was the principal investigator the first prospective randomized study with control group evaluating the efficacy and safety of electronic cigarettes on a sample of 300 smokers unwilling to quit. [10]
He serves as an external member of the Technical Committee of the Italian Institute of Health (ISS). [11] He is also the National Coordinator for the Italian Working Group on "Electronic cigarettes and e-liquids" and has been recently elected Convener for the Working Group on "Requirements and test methods for emissions of electronic cigarettes", within the European Committee for Standardization. [12]
In May 2020, he launched the Catania Conversation, a science communication initiative that seeks to bring the best of science and media to the high table where policy decisions are debated and decided. [13]
He specialized in the field of tobacco smoking, tobacco harm reduction, and electronic cigarettes. His work contributed to a 2015 paper that found that "e-cigarettes were 95% less harmful than tobacco cigarettes". This finding has been criticized by The Lancet . He also challenged claims that vaping poses a risk during the COVID-19 pandemic.
As CoEHAR founder and scientific director, Polosa invests in scientific and technological innovation to promote and evaluate effective and less harmful solutions than combustible smoking. He has led innovative research projects which, through the development of apps, provide daily support for diabetic patients to quit smoking. First of all, the Diasmoke Project.
DIASMOKE (Assessing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) is an international, multicenter, open-label randomized controlled study designed to determine whether diabetic smokers switching to combustion-free nicotine delivery systems (C-F NDS) experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.
This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when type 2 diabetes mellitus patients who smoke switch to alternative products compared with diabetic patients who continue to smoke conventional tobacco products.
Riccardo Polosa has recently conducted studies on the relationship between cigarette smoking, contagion, and disease caused by the virus. Among the most important papers, he published: COVID-19 and Obesity: Dangerous Liaisons; Seroepidemiological Survey on the Impact of Smoking on SARS-CoV-2 Infection and COVID-19 Outcomes: Protocol for the Troina Study; The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina seroepidemiological survey; Smoking and SARS-CoV-2 Disease (COVID-19); Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments
Riccardo Polosa is the author of over 411 scientific publications [14] most of which are articles published in extenso in international scientific journals (H index equal to 56 –Citation Index total equal to 12104 - source: Scopus). [14] For the complete list of all publications, refer to PubMed and EMBASE databases
In addition, Polosa is also author of over 30 chapters on national and international volumes and is the Chief Editor of two international volumes published in 2007 and one in 2009. [15] He is also among the curators of the Italian edition of AA.VV. Macleod - Manuale di semeiotica e metodologia medica, Edra Elsevier, Milan 2014. [16]
Polosa has held several public positions, he was secretary and then chair of the "Airway Regulation, Provocation and Monitoring" Group of the European Respiratory Society, [17] Chair for the "Diagnosis and Therapeutics Committee" of the American Academy of Allergy Asthma and Immunology, and Founder of the University Center of Excellence for the acceleration of Harm Reduction (CoEHAR).
Riccardo Polosa collaborates as a reviewer of the Italian Ministry of Health for ECM activities in the field of Respiratory Diseases and the field Clinical Immunology and Allergology. [18] He is Coordinator of the UNI Working Group on " Electronic cigarettes and e-liquids” and convenor of the CEN European Working Group on " Requirements and test methods for emissions of electronic cigarettes. [19] Riccardo Polosa is Coordinator of the Italian Working Group UNI/CT 042/GL 67 "Electronic cigarettes and e- liquids" and Convenor of the European Working Group 4 "Requirements and test methods for emissions of electronic cigarettes", (CEN/TC 437). [20] Polosa is also a member of the Technical Committee of the Italian Institute of Health on monitoring electronic cigarettes. [21]
Polosa is Associate Editor for Internal and Emergency Medicine, Therapeutic Advances in Chronic Disease, International Journal of Environmental Research and Public Health.
A cigarette is a narrow cylinder containing a combustible material, typically tobacco, that is rolled into thin paper for smoking. The cigarette is ignited at one end, causing it to smolder; the resulting smoke is orally inhaled via the opposite end. Cigarette smoking is the most common method of tobacco consumption. The term cigarette, as commonly used, refers to a tobacco cigarette, but the word is sometimes used to refer to other substances, such as a cannabis cigarette or a herbal cigarette. A cigarette is distinguished from a cigar by its usually smaller size, use of processed leaf, different smoking method, and paper wrapping, which is typically white.
Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise.
Tobacco smoke is a sooty aerosol produced by the incomplete combustion of tobacco during the smoking of cigarettes and other tobacco products. Temperatures in burning cigarettes range from about 400 °C between puffs to about 900 °C during a puff. During the burning of the cigarette tobacco, thousands of chemical substances are generated by combustion, distillation, pyrolysis and pyrosynthesis. Tobacco smoke is used as a fumigant and inhalant.
A vaporizer or vaporiser, colloquially known as a vape, is a device used to vaporize substances for inhalation. Plant substances can be used, commonly cannabis, tobacco, or other herbs or blends of essential oil. However, they are most commonly filled with a combination propylene glycol, glycerin, and drugs such as nicotine or tetrahydrocannabinol as a liquid solution.
Tobacco products, especially when smoked or used orally, have serious negative effects on human health. Smoking and smokeless tobacco use is the single greatest cause of preventable death globally. As many as half of people who smoke tobacco or use it orally die from complications related to such use. It has been estimated that each year, in total about 6 million people die from tobacco-related causes, with 600,000 of these occurring in non-smokers due to secondhand smoke. It is further estimated to have caused 100 million deaths in the 20th century.
Tobacco harm reduction (THR) is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. It is an example of the concept of harm reduction, a strategy for dealing with the use of drugs. Tobacco smoking is widely acknowledged as a leading cause of illness and death, and reducing smoking is vital to public health.
An electronic cigarette (e-cigarette) or vape is a vaporizer device that simulates tobacco smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank. Instead of smoke, the user inhales vapor. As such, using an e-cigarette is often called "vaping". The atomizer is a heating element that vaporizes a liquid solution called e-liquid, which quickly cools into an aerosol of tiny droplets, vapor and air. The vapor mainly comprises propylene glycol and/or glycerin, usually with nicotine and flavoring. Its exact composition varies, and depends on several things including user behavior.
Stanton Arnold Glantz is an American professor, author, and tobacco control activist. Glantz is a faculty member at the University of California, San Francisco (UCSF) School of Medicine, where he is a Professor of Medicine (retired) in the Division of Cardiology, the American Legacy Foundation Distinguished Professor of Tobacco Control, and former director of the Center for Tobacco Control Research and Education. Glantz's research focused on the health effects of tobacco smoking.
Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing (obstruction) of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling, and frequent medical clinic visits and hospitalizations. Types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms, and reversibility of airway obstruction. Cystic fibrosis is also sometimes included in obstructive pulmonary disease.
Respiratory Health Association is a nonprofit organization located on Chicago's Near West Side.
Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.
The Dutch hypothesis provides one of several biologically plausible explanations for the pathogenesis of chronic obstructive pulmonary disease (COPD), a progressive disease known to be aetiologically linked to environmental insults such as tobacco smoke.
Igor Petrovych Kaidashev is a Ukrainian immunologist and allergist, MD, and Professor. Igor Kaidashev is President of the Ukrainian Society of Immunology, Allergy and Immunorehabilitation, Professor of the Department of Internal Medicine No. 3 with Phthisiology, and Vice-Rector for Research & Development at Poltava State Medical University (PSMU) since 2010.
The health effects of electronic cigarettes (e-cigarettes) include a range of potential risks such as exposure to toxic chemicals, the possibility of increased likelihood of respiratory and cardiovascular diseases, and concerns about their possible role in cancer development. Upon their introduction, there were marketing claims that they were a safer alternative to traditional tobacco products.
The scientific community in the United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking, weaken measures to control tobacco, and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes, because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits, but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did, as a result of chronic exposure", among other things.
The chemical composition of the electronic cigarette aerosol varies across and within manufacturers. Limited data exists regarding their chemistry. However, researchers at Johns Hopkins University analyzed the vape clouds of popular brands such as Juul and Vuse, and found "nearly 2,000 chemicals, the vast majority of which are unidentified."
The Foundation for a Smoke-Free World is an organization focused on smoking harm reduction founded in 2017. In May 2024, it changed its name to Global Action to End Smoking. The World Health Organization (WHO) urged not to collaborate with this front organization of the tobacco industry.
Giorgio Walter Canonica is an Italian allergist, pulmonologist and professor of Respiratory Medicine at Humanitas University, Milan, Italy and Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital IRCCS-Milano Italy since December 2016. He is known for his research work related to innovative treatment strategies for allergic diseases which includes biological response modifier in form of targeted immunotherapy with primary emphasis on sublingual immunotherapy (SLIT). He has served as Secretary General and President elect of World Allergy Organisation for six consecutive years and has served as president of the same organization during 2007–09. He is also the vice-president of INTERASMA.
Smoker's macrophages are alveolar macrophages whose characteristics, including appearance, cellularity, phenotypes, immune response, and other functions, have been affected upon the exposure to cigarettes. These altered immune cells are derived from several signaling pathways and are able to induce numerous respiratory diseases. They are involved in asthma, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, and lung cancer. Smoker’s macrophages are observed in both firsthand and secondhand smokers, so anyone exposed to cigarette contents, or cigarette smoke extract (CSE), would be susceptible to these macrophages, thus in turns leading to future complications.
Natalie K. Walker is a New Zealand academic, and is a Professor of Social and Community Health at the University of Auckland, specialising in the reduction of harm from non-communicable diseases such as cardiovascular disease and cancer. She has an interest in smoking cessation but also researches on alcohol, cannabis and sugar.
{{cite book}}
: |website=
ignored (help)